XPH vs. IDNA
XPH (SPDR S&P Pharmaceuticals ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds - XPH tracks the S&P Pharmaceuticals Select Industry Index while IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. Both are passively managed. Over the past 5 years, XPH returned 3.50%/yr vs -8.42%/yr for IDNA. A 0.74 correlation means they provide meaningful diversification when combined. XPH charges 0.35%/yr vs 0.47%/yr for IDNA.
Performance
XPH vs. IDNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XPH achieves a 0.66% return, which is significantly lower than IDNA's 10.31% return.
XPH
- 1D
- 1.10%
- 1M
- -4.74%
- YTD
- 0.66%
- 6M
- 4.44%
- 1Y
- 37.98%
- 3Y*
- 13.07%
- 5Y*
- 3.50%
- 10Y*
- 3.44%
IDNA
- 1D
- 0.73%
- 1M
- -2.56%
- YTD
- 10.31%
- 6M
- 8.52%
- 1Y
- 40.87%
- 3Y*
- 6.74%
- 5Y*
- -8.42%
- 10Y*
- —
XPH vs. IDNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | 0.66% | 31.60% | 4.94% | 2.97% | -9.83% | -10.54% | 14.68% | 21.53% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 10.31% | 17.26% | -0.72% | -7.63% | -42.28% | -3.98% | 54.30% | 20.83% |
Correlation
The correlation between XPH and IDNA is 0.76, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.76 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.74 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.74 |
Correlation (All Time) Calculated using the full available price history since Jun 14, 2019 | 0.74 |
The correlation between XPH and IDNA has been stable across timeframes, ranging from 0.73 to 0.76 - a consistent structural relationship.
XPH vs. IDNA - Sectors Allocation Comparison
Sectors
XPH
IDNA
Healthcare
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Industrials
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
XPH
IDNA
Basic Materials
XPH
-
IDNA
-
Communication Services
XPH
-
IDNA
-
Consumer Cyclical
XPH
-
IDNA
-
Consumer Defensive
XPH
-
IDNA
-
Energy
XPH
-
IDNA
-
Financial Services
XPH
-
IDNA
-
Industrials
XPH
-
IDNA
Real Estate
XPH
-
IDNA
-
Technology
XPH
-
IDNA
-
Utilities
XPH
-
IDNA
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XPH vs. IDNA — Risk / Return Rank
XPH
IDNA
XPH vs. IDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XPH | IDNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.09 | ||
| Sortino ratioReturn per unit of downside risk | +0.07 | ||
| Omega ratioGain probability vs. loss probability | 1.30 | 1.27 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 3.19 | 3.85 | -0.66 |
| Martin ratioReturn relative to average drawdown | 11.37 | 10.98 | +0.40 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| XPH | IDNA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.77 | 1.68 | +0.09 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.17 | -0.30 | +0.47 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.16 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.38 | 0.10 | +0.28 |
Drawdowns
XPH vs. IDNA - Drawdown Comparison
The maximum XPH drawdown since its inception was -48.03%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for XPH and IDNA.
Loading charts...
Drawdown Indicators
| XPH | IDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -48.03% | -68.26% | +20.23% |
Max Drawdown (1Y)Largest decline over 1 year | -11.97% | -10.66% | -1.31% |
Max Drawdown (3Y)Largest decline over 3 years | -23.57% | -29.73% | +6.16% |
Max Drawdown (5Y)Largest decline over 5 years | -31.63% | -68.26% | +36.63% |
Max Drawdown (10Y)Largest decline over 10 years | -35.97% | — | — |
Current DrawdownCurrent decline from peak | -7.22% | -45.61% | +38.39% |
Average DrawdownAverage peak-to-trough decline | -17.25% | -36.24% | +18.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.35% | 3.73% | -0.38% |
Volatility
XPH vs. IDNA - Volatility Comparison
SPDR S&P Pharmaceuticals ETF (XPH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) have volatilities of 7.03% and 7.18%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XPH | IDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.03% | 7.18% | -0.15% |
Volatility (6M)Calculated over the trailing 6-month period | 16.77% | 17.98% | -1.21% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.52% | 24.48% | -2.96% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.84% | 28.42% | -7.58% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.10% | 29.53% | -7.43% |
XPH vs. IDNA - Expense Ratio Comparison
XPH has a 0.35% expense ratio, which is lower than IDNA's 0.47% expense ratio.
Dividends
XPH vs. IDNA - Dividend Comparison
XPH's dividend yield for the trailing twelve months is around 0.66%, less than IDNA's 1.07% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.07% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% |
XPH SPDR S&P Pharmaceuticals ETF | 0.66% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
Frequently Asked Questions
XPH and IDNA have a correlation of 0.76, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
IDNA has higher volatility (7.18%) compared to XPH (7.03%). In terms of maximum drawdown, XPH dropped -48.03% vs IDNA's -68.26%.
On 5-year performance, XPH leads with 3.50% vs -8.42% for IDNA. On fees, XPH is cheaper at 0.35% per year. On volatility, XPH has been the lower-risk option at 7.03%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, XPH has performed better with a 3.50% return vs -8.42%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XPH is cheaper with a 0.35% expense ratio, compared with 0.47% for IDNA.
IDNA has the higher dividend yield at 1.07%, compared with 0.66% for XPH.
XPH tracks S&P Pharmaceuticals Select Industry Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: State Street and iShares. Their fees differ too: 0.35% for XPH and 0.47% for IDNA.
XPH currently has the higher Sharpe Ratio (1.77 vs 1.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XPH and IDNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer